{"protocolSection": {"identificationModule": {"nctId": "NCT01958671", "orgStudyIdInfo": {"id": "8835-003"}, "secondaryIdInfos": [{"id": "2013-002519-90", "type": "EUDRACT_NUMBER"}, {"id": "B1521022", "type": "OTHER", "domain": "Pfizer Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)", "officialTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-10-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-07-28", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-07-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-10-07", "studyFirstSubmitQcDate": "2013-10-07", "studyFirstPostDateStruct": {"date": "2013-10-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-07-14", "resultsFirstSubmitQcDate": "2017-09-01", "resultsFirstPostDateStruct": {"date": "2017-09-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-09-01", "lastUpdatePostDateStruct": {"date": "2017-09-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise. This trial consists of a run-in period of 3 to 11 weeks, a 26-week placebo-controlled treatment period (Phase A), and a 26-week active treatment period (Phase B). The primary hypotheses of the trial are that at Week 26, the mean reduction from baseline in hemoglobin A1c (A1C) for 15 mg ertugliflozin is greater than that for placebo and the mean reduction from baseline in A1C for 5 mg ertugliflozin is greater than that for placebo."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 461, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "type": "EXPERIMENTAL", "description": "Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.", "interventionNames": ["Drug: Ertugliflozin 5 mg", "Drug: Placebo to Ertugliflozin", "Drug: Metformin", "Drug: Placebo to Metformin", "Drug: Glimepiride"]}, {"label": "Ertugliflozin 15 mg/Ertugliflozin 15 mg", "type": "EXPERIMENTAL", "description": "Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.", "interventionNames": ["Drug: Ertugliflozin 5 mg", "Drug: Ertugliflozin 10 mg", "Drug: Metformin", "Drug: Placebo to Metformin", "Drug: Glimepiride"]}, {"label": "Placebo/Metformin", "type": "OTHER", "description": "Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Metformin", "Drug: Glimepiride"]}], "interventions": [{"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).", "armGroupLabels": ["Ertugliflozin 15 mg/Ertugliflozin 15 mg", "Ertugliflozin 5 mg/Ertugliflozin 5 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Ertugliflozin 10 mg", "description": "One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).", "armGroupLabels": ["Ertugliflozin 15 mg/Ertugliflozin 15 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Placebo to Ertugliflozin", "description": "One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).", "armGroupLabels": ["Ertugliflozin 5 mg/Ertugliflozin 5 mg", "Placebo/Metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.", "armGroupLabels": ["Ertugliflozin 15 mg/Ertugliflozin 15 mg", "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "Placebo/Metformin"], "otherNames": ["Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor and Metfogamma."]}, {"type": "DRUG", "name": "Placebo to Metformin", "description": "1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.", "armGroupLabels": ["Ertugliflozin 15 mg/Ertugliflozin 15 mg", "Ertugliflozin 5 mg/Ertugliflozin 5 mg"]}, {"type": "DRUG", "name": "Glimepiride", "description": "Dosing and titration of glimepiride as rescue therapy was determined by the investigator.", "armGroupLabels": ["Ertugliflozin 15 mg/Ertugliflozin 15 mg", "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "Placebo/Metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline In A1C at Week 26", "description": "A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Experiencing An Adverse Event (AE)", "description": "An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "timeFrame": "Up to 54 weeks (including 2 weeks following last dose)"}, {"measure": "Percentage of Participants Discontinuing Study Treatment Due to an AE", "description": "An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "timeFrame": "Up to 52 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FPG at Week 26", "description": "The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Body Weight at Week 26", "description": "The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26", "description": "A1C is measured as percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level", "description": "Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in 2-hr PPG at Week 26", "description": "The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Baseline Sitting Systolic Blood Pressure (SBP)", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in SBP at Week 26", "description": "The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Baseline Sitting Diastolic Blood Pressure (DBP)", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in DBP at Week 26", "description": "The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of T2DM in accordance to American Diabetes Association guidelines\n* Participants with no prior allowable oral anti-hyperglycemic agents (AHA) for at least 8 weeks prior to study participation or participants on a single allowable oral AHA at the start of study participation\n* Participants on a single allowable AHA must be willing to discontinue this medication at the Screening Visit (S2) and remain off this medication for the duration of the trial. Allowable oral AHAs for discontinuation are metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides or alpha-glucosidase inhibitors.\n\nExclusion Criteria:\n\n* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation\n* A clinically significant electrocardiogram abnormality\n* A history of malignancy \u22645 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer\n* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor or metformin\n* On a blood pressure or lipid altering medication that have not been on a stable dose for at least 4 weeks prior to study participation\n* A surgical procedure within 4 weeks prior to study participation or planned major surgery during the trial\n* Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial\n* Pregnant or breast-feeding, or is expecting to conceive during the trial, including 14 days following the last dose of study drug", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "28116776", "type": "RESULT", "citation": "Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May;19(5):721-728. doi: 10.1111/dom.12888. Epub 2017 Feb 22."}, {"pmid": "34213819", "type": "DERIVED", "citation": "Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2."}, {"pmid": "32700393", "type": "DERIVED", "citation": "Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27."}, {"pmid": "32648108", "type": "DERIVED", "citation": "Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9."}, {"pmid": "32372382", "type": "DERIVED", "citation": "Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5."}, {"pmid": "32324082", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13."}, {"pmid": "32324065", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13."}, {"pmid": "31797522", "type": "DERIVED", "citation": "Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3."}, {"pmid": "31064361", "type": "DERIVED", "citation": "Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7."}, {"pmid": "29419917", "type": "DERIVED", "citation": "Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018 Jun;20(6):1453-1460. doi: 10.1111/dom.13251. Epub 2018 Feb 23."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "description": "Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "FG001", "title": "Ertugliflozin 15 mg/Ertugliflozin 15 mg", "description": "Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "FG002", "title": "Placebo/Metformin", "description": "Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "156"}, {"groupId": "FG001", "numSubjects": "152"}, {"groupId": "FG002", "numSubjects": "153"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "137"}, {"groupId": "FG001", "numSubjects": "128"}, {"groupId": "FG002", "numSubjects": "121"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Excluded medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Hyperglycemia", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Study site terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Participant moved", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "13"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "description": "Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "BG001", "title": "Ertugliflozin 15 mg/Ertugliflozin 15 mg", "description": "Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "BG002", "title": "Placebo/Metformin", "description": "Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "461"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "461"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "56.8", "spread": "11.4"}, {"groupId": "BG001", "value": "56.2", "spread": "10.8"}, {"groupId": "BG002", "value": "56.1", "spread": "10.9"}, {"groupId": "BG003", "value": "56.4", "spread": "11.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "461"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "71"}, {"groupId": "BG003", "value": "200"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "82"}, {"groupId": "BG003", "value": "261"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "populationDescription": "All randomized participants who received at least 1 dose of study treatment and had baseline A1C measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "151"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "459"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.16", "spread": "0.88"}, {"groupId": "BG001", "value": "8.35", "spread": "1.12"}, {"groupId": "BG002", "value": "8.11", "spread": "0.92"}, {"groupId": "BG003", "value": "8.21", "spread": "0.98"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "populationDescription": "All randomized participants who received at least 1 dose of study treatment and had baseline FPG measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "149"}, {"groupId": "BG002", "value": "150"}, {"groupId": "BG003", "value": "450"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "180.9", "spread": "48.5"}, {"groupId": "BG001", "value": "179.1", "spread": "48.2"}, {"groupId": "BG002", "value": "180.2", "spread": "45.8"}, {"groupId": "BG003", "value": "180.1", "spread": "47.4"}]}]}]}, {"title": "Estimated glomerular filtration rate (eGFR)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.75m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "461"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "88.5", "spread": "18.4"}, {"groupId": "BG001", "value": "88.3", "spread": "18.0"}, {"groupId": "BG002", "value": "86.2", "spread": "19.4"}, {"groupId": "BG003", "value": "87.7", "spread": "18.6"}]}]}]}, {"title": "Body weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "461"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "94.0", "spread": "25.4"}, {"groupId": "BG001", "value": "90.6", "spread": "18.3"}, {"groupId": "BG002", "value": "94.2", "spread": "25.2"}, {"groupId": "BG003", "value": "92.9", "spread": "23.2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline In A1C at Week 26", "description": "A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline A1C measurement or at least 1 post-randomization A1C measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.79", "lowerLimit": "-0.95", "upperLimit": "-0.63"}, {"groupId": "OG001", "value": "-0.96", "lowerLimit": "-1.12", "upperLimit": "-0.80"}, {"groupId": "OG002", "value": "0.20", "lowerLimit": "0.02", "upperLimit": "0.37"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.22", "ciUpperLimit": "-0.76"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-1.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.39", "ciUpperLimit": "-0.93"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Experiencing An Adverse Event (AE)", "description": "An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were classified according to randomized treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 54 weeks (including 2 weeks following last dose)", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "description": "Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "OG001", "title": "Ertugliflozin 15 mg/Ertugliflozin 15 mg", "description": "Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "OG002", "title": "Placebo/Metformin", "description": "Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "64.1"}, {"groupId": "OG001", "value": "62.5"}, {"groupId": "OG002", "value": "66.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-2.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.1", "ciUpperLimit": "8.1", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-4.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.8", "ciUpperLimit": "6.6", "estimateComment": "Based on Miettinen \\& Nurminen method."}]}, {"type": "PRIMARY", "title": "Percentage of Participants Discontinuing Study Treatment Due to an AE", "description": "An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were classified according to randomized treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 52 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "description": "Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "OG001", "title": "Ertugliflozin 15 mg/Ertugliflozin 15 mg", "description": "Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}, {"id": "OG002", "title": "Placebo/Metformin", "description": "Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.5"}, {"groupId": "OG001", "value": "3.9"}, {"groupId": "OG002", "value": "6.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-2.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.7", "ciUpperLimit": "3.3", "estimateComment": "Based on Miettinen \\& Nurminen method."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-2.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.2", "ciUpperLimit": "2.7", "estimateComment": "Based on Miettinen \\& Nurminen method."}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 26", "description": "The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline FPG measurement or at least 1 post-randomization FPG measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.96", "lowerLimit": "-39.85", "upperLimit": "-28.06"}, {"groupId": "OG001", "value": "-43.44", "lowerLimit": "-49.39", "upperLimit": "-37.49"}, {"groupId": "OG002", "value": "0.57", "lowerLimit": "-6.02", "upperLimit": "7.16"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-34.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-42.76", "ciUpperLimit": "-26.29"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-44.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-52.28", "ciUpperLimit": "-35.74"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 26", "description": "The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline body weight measurement or at least 1 post-randomization body weight measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.18", "lowerLimit": "-3.72", "upperLimit": "-2.63"}, {"groupId": "OG001", "value": "-3.58", "lowerLimit": "-4.13", "upperLimit": "-3.02"}, {"groupId": "OG002", "value": "-1.42", "lowerLimit": "-2.02", "upperLimit": "-0.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-1.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.57", "ciUpperLimit": "-0.95"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-2.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.98", "ciUpperLimit": "-1.34"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26", "description": "A1C is measured as percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline A1C measurement or at least 1 post-randomization A1C measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.2"}, {"groupId": "OG001", "value": "35.8"}, {"groupId": "OG002", "value": "13.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Fixed effects for treatment, prior antihyperglycemic medication, covariates for baseline A1C and baseline eGFR.", "paramType": "Odds Ratio (OR)", "paramValue": "3.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.85", "ciUpperLimit": "6.95"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Fixed effects for treatment, prior antihyperglycemic medication, covariates for baseline A1C and baseline", "paramType": "Odds Ratio (OR)", "paramValue": "6.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.46", "ciUpperLimit": "13.24"}]}, {"type": "SECONDARY", "title": "Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level", "description": "Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.", "populationDescription": "Analysis population consisted of all randomized participants who had a baseline 2-hr PPG measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "260.32", "spread": "76.110"}, {"groupId": "OG001", "value": "262.91", "spread": "78.189"}, {"groupId": "OG002", "value": "256.21", "spread": "76.917"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hr PPG at Week 26", "description": "The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline 2-hr PPG measurement or at least 1 post-randomization 2-hr PPG measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-64.15", "lowerLimit": "-74.34", "upperLimit": "-53.96"}, {"groupId": "OG001", "value": "-62.45", "lowerLimit": "-72.91", "upperLimit": "-51.98"}, {"groupId": "OG002", "value": "4.88", "lowerLimit": "-6.15", "upperLimit": "15.92"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-69.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-83.24", "ciUpperLimit": "-54.83"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-67.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-81.73", "ciUpperLimit": "-52.93"}]}, {"type": "SECONDARY", "title": "Baseline Sitting Systolic Blood Pressure (SBP)", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.", "populationDescription": "Analysis population consisted of all randomized participants who had a baseline SBP measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "130.49", "spread": "13.511"}, {"groupId": "OG001", "value": "129.67", "spread": "14.208"}, {"groupId": "OG002", "value": "129.80", "spread": "14.464"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in SBP at Week 26", "description": "The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline SBP measurement or at least 1 post-randomization SBP measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "152"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.54", "lowerLimit": "-7.32", "upperLimit": "-3.76"}, {"groupId": "OG001", "value": "-3.93", "lowerLimit": "-5.74", "upperLimit": "-2.12"}, {"groupId": "OG002", "value": "-2.22", "lowerLimit": "-4.30", "upperLimit": "-0.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.015", "pValueComment": "Nominal p-value", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-3.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.98", "ciUpperLimit": "-0.65"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.213", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-1.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.40", "ciUpperLimit": "0.98"}]}, {"type": "SECONDARY", "title": "Baseline Sitting Diastolic Blood Pressure (DBP)", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.", "populationDescription": "Analysis population consisted of all randomized participants who had a baseline DBP measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "78.46", "spread": "8.117"}, {"groupId": "OG001", "value": "78.53", "spread": "7.714"}, {"groupId": "OG002", "value": "78.13", "spread": "7.458"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in DBP at Week 26", "description": "The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline DBP measurement or at least 1 post-randomization DBP measurement subsequent to at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Participants received ertugliflozin 5 mg once daily for 26 weeks."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Participants received ertugliflozin 15 mg once daily for 26 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to ertugliflozin once daily for 26 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "152"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.52", "lowerLimit": "-3.65", "upperLimit": "-1.40"}, {"groupId": "OG001", "value": "-1.10", "lowerLimit": "-2.24", "upperLimit": "0.05"}, {"groupId": "OG002", "value": "-0.72", "lowerLimit": "-2.05", "upperLimit": "0.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.039", "pValueComment": "Nominal p-value", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Odds Ratio (OR)", "paramValue": "-1.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.51", "ciUpperLimit": "-0.09"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.669", "pValueComment": "Nominal p-value", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.", "paramType": "Difference in least squares means", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.09", "ciUpperLimit": "1.35"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 54 weeks (+/- 3 days)", "description": "Data presented below include data following the initiation of rescue therapy for the entire study (ie, all data after randomization, with no upper limit on the follow-up window for participants who discontinued study drug).", "eventGroups": [{"id": "EG000", "title": "Ertugliflozin 5 mg/Ertugliflozin 5 mg", "description": "Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.", "seriousNumAffected": 11, "seriousNumAtRisk": 156, "otherNumAffected": 50, "otherNumAtRisk": 156}, {"id": "EG001", "title": "Ertugliflozin 15 mg/Ertugliflozin 15 mg", "description": "Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.", "seriousNumAffected": 6, "seriousNumAtRisk": 152, "otherNumAffected": 48, "otherNumAtRisk": 152}, {"id": "EG002", "title": "Placebo/Metformin", "description": "Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.", "seriousNumAffected": 8, "seriousNumAtRisk": 153, "otherNumAffected": 68, "otherNumAtRisk": 153}], "seriousEvents": [{"term": "Papilloedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Retinal artery occlusion", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Ulcerative keratitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Bacterial infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Cellulitis of male external genital organ", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Periorbital abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Periorbital cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Hepatic cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Squamous cell carcinoma of lung", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Squamous cell carcinoma of the cervix", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Ruptured cerebral aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Bipolar disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Blindness transient", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}], "otherEvents": [{"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 153}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 26, "numAffected": 23, "numAtRisk": 153}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 14, "numAffected": 12, "numAtRisk": 153}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 153}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 12, "numAffected": 11, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 153}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 15, "numAffected": 9, "numAtRisk": 153}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 13, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 14, "numAffected": 10, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 30, "numAffected": 19, "numAtRisk": 153}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 12, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 11, "numAffected": 8, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 153}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 14, "numAffected": 6, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 23, "numAffected": 10, "numAtRisk": 153}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 6, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 152}, {"groupId": "EG002", "numEvents": 9, "numAffected": 9, "numAtRisk": 153}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, investigator agrees to delay the disclosure for a period not to exceed an additional 60 days."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Israel", "Italy", "Mexico", "South Africa", "United Kingdom", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}]}}, "hasResults": true}